Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “outperform” rating reissued by analysts at William Blair in a research note issued on Thursday, Zacks.com reports.

DVAX has been the subject of several other research reports. Zacks Investment Research upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub upgraded shares of Dynavax Technologies from a “strong sell” rating to a “sell” rating in a research report on Tuesday. ValuEngine cut shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price (down from $32.00) on shares of Dynavax Technologies in a research report on Tuesday, February 26th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Dynavax Technologies presently has a consensus rating of “Hold” and an average price target of $27.67.

Shares of DVAX stock traded up $0.20 during midday trading on Thursday, hitting $7.89. 2,017,833 shares of the company were exchanged, compared to its average volume of 865,043. The company has a market capitalization of $500.34 million, a price-to-earnings ratio of -3.09 and a beta of 0.60. The company has a debt-to-equity ratio of 1.60, a quick ratio of 4.08 and a current ratio of 4.58. Dynavax Technologies has a 52 week low of $6.22 and a 52 week high of $20.10.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. The business had revenue of $5.77 million during the quarter, compared to the consensus estimate of $5.95 million. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 164.33%. Dynavax Technologies’s revenue was up 3294.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.63) EPS. Sell-side analysts forecast that Dynavax Technologies will post -2.22 EPS for the current year.

In other news, VP David Louis Johnson sold 20,765 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total value of $187,507.95. Following the completion of the transaction, the vice president now directly owns 52,786 shares in the company, valued at approximately $476,657.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michael S. Ostrach sold 35,444 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $8.94, for a total transaction of $316,869.36. Following the completion of the transaction, the insider now owns 121,581 shares of the company’s stock, valued at $1,086,934.14. The disclosure for this sale can be found here. Insiders sold a total of 119,411 shares of company stock valued at $1,075,091 over the last 90 days. Corporate insiders own 3.47% of the company’s stock.

Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its stake in shares of Dynavax Technologies by 6.0% in the 3rd quarter. Wells Fargo & Company MN now owns 87,721 shares of the biopharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 4,979 shares during the last quarter. BlackRock Inc. raised its holdings in Dynavax Technologies by 1.4% during the third quarter. BlackRock Inc. now owns 4,123,662 shares of the biopharmaceutical company’s stock worth $51,134,000 after buying an additional 56,568 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Dynavax Technologies by 1.8% during the third quarter. JPMorgan Chase & Co. now owns 264,669 shares of the biopharmaceutical company’s stock worth $3,282,000 after buying an additional 4,591 shares during the last quarter. MetLife Investment Advisors LLC raised its holdings in Dynavax Technologies by 55.5% during the third quarter. MetLife Investment Advisors LLC now owns 44,609 shares of the biopharmaceutical company’s stock worth $553,000 after buying an additional 15,919 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Dynavax Technologies by 1.0% during the third quarter. Vanguard Group Inc. now owns 2,883,887 shares of the biopharmaceutical company’s stock worth $35,759,000 after buying an additional 29,898 shares during the last quarter. Institutional investors own 83.95% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Recommended Story: Market Capitalization

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.